Catalysts / SGMT
Upcoming FDA decisions and readouts we track for Sagimet Biosciences, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Sagimet Biosciences (SGMT, listed on Nasdaq). It concerns TVB-3567 (Acne (FASN inhibitor)).
First on the list: the Phase 1 readout for TVB-3567 (Acne (FASN inhibitor)), guided by the company to 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Sagimet Biosciences SGMT · Nasdaq | TVB-3567 | Acne (FASN inhibitor) | 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList